Trials / Completed
CompletedNCT04257500
Does Vaginal Delivery of Combined Hormonal Contraception Affect the Risk of Metabolic Syndrome in Overweight/Obese Women With PCOS
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Andrea Roe, MD, MPH · Academic / Other
- Sex
- Female
- Age
- 18 Years – 40 Years
- Healthy volunteers
- Not accepted
Summary
A prospective study to determine the metabolic effects of the contraceptive vaginal ring among overweight and obese women with polycystic ovary syndrome (PCOS). We will recruit a total of 40 participants and study use of the vaginal ring over a 4-month period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Etonogestrel/ethinyl estradiol vaginal ring | 16 weeks of continuous use of contraceptive vaginal ring |
Timeline
- Start date
- 2020-09-03
- Primary completion
- 2025-08-22
- Completion
- 2025-08-22
- First posted
- 2020-02-06
- Last updated
- 2025-12-17
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04257500. Inclusion in this directory is not an endorsement.